Skip to content
Agree.net – Lifestyle
Author:
Spyre Therapeutics, Inc.
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
June 15, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
June 5, 2026
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
June 3, 2026
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
May 26, 2026
RideNow Group, Inc. Reports First Quarter 2026 Financial Results
May 15, 2026
RideNow Group, Inc. to Report First Quarter 2026 Earnings on May 14, 2026
May 8, 2026
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 5, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
May 1, 2026
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 16, 2026
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
April 14, 2026
1
2
Next Page
→